{"contentid": 488399, "importid": NaN, "name": "Enhertu recommended for CDF inclusion in England", "introduction": "The National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) to treat HER2 positive unresectable or metastatic breast cancer in English adults who have received two or more prior anti-HER2 based therapies.", "content": "<p>The UK's National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) to treat HER2 positive unresectable or metastatic breast cancer in English adults who have received two or more prior anti-HER2 based therapies.</p>\n<p>Daiichi Sankyo (TYO: 4568) and AstraZeneca (LSE: AZN) entered into a global collaboration to jointly develop and commercialize Enhertu in March 2019, except in Japan where the Japanese firm maintains exclusive rights.</p>\n<p><span class=\"pullQuote\">\"Though many treatment advances have been made in HER2 positive metastatic breast cancer, there has been no clear standard of care for patients following progression after second line treatment and many patients do not have a durable response to other available later-line options\"</span>They will continue working in close partnership with the NICE as additional data are collected throughout the managed access period. During this time, eligible patients will be able to access Enhertu in advance of a decision from the NICE on routine funding on the National Health Service.</p>\n<p>The CDF recommendation is applicable to patients in England. Discussions with Welsh and Northern Irish health authorities are ongoing and the submission for the appraisal of Enhertu to the Scottish Medicines Consortium is currently in development, with a decision expected later in 2021.</p>\n<p>In the UK, almost 54,000 cases of breast cancer in women are diagnosed annually, with an estimated one in five cases being HER2 positive.</p>\n<p>The impact of the disease is significant, with breast cancer responsible for approximately 12,000 deaths per year. There are an estimated 35,000 people living with metastatic breast cancer in the UK, and in around 5% of women the breast cancer has already spread by the time it is diagnosed.</p>\n<p>Arun Krishna, head of oncology, AstraZeneca UK, said: \"Though many treatment advances have been made in HER2 positive metastatic breast cancer, there has been no clear standard of care for patients following progression after second line treatment and many patients do not have a durable response to other available later-line options.\"</p>\n<p>&ldquo;To know that patients in England now have access to a new treatment option is welcome news indeed.&rdquo;</p>", "date": "2021-04-20 11:57:00", "meta_title": NaN, "meta_keywords": "cancer, Enhertu, breast, patients, positive, metastatic, recommended, care, treatment, NICE, health, National, England, inclusion, Excellence, Institute", "meta_description": "The National Institute for Health and Care Excellence (NICE) has recommended Enhertu (trastuzumab deruxtecan) for use within the Cancer Drugs Fund (CDF) to trea", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 3, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-04-20 11:53:07", "updated": "2021-04-20 12:10:54", "access": NaN, "url": "https://www.thepharmaletter.com/article/enhertu-recommended-for-cdf-inclusion-in-england", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "nice-big-1.png", "image2id": "nice-small.png", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": "Oncology", "topic_tag": "Focus On, Pricing, reimbursement and access", "geography_tag": "Japan, Sweden, UK", "company_tag": "AstraZeneca, Daiichi Sankyo", "drug_tag": "Enhertu", "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-04-20 11:57:00"}